JP2010510211A - 免疫抑制用７−置換プリン誘導体 - Google Patents

免疫抑制用７−置換プリン誘導体 Download PDF

Info

Publication number
JP2010510211A
JP2010510211A JP2009537135A JP2009537135A JP2010510211A JP 2010510211 A JP2010510211 A JP 2010510211A JP 2009537135 A JP2009537135 A JP 2009537135A JP 2009537135 A JP2009537135 A JP 2009537135A JP 2010510211 A JP2010510211 A JP 2010510211A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclyl
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009537135A
Other languages
English (en)
Japanese (ja)
Inventor
マイケル・オールマイヤー
アドルフ・ボーンステッド
セリア・キングスベリー
コク−カン・ホ
ジョージ・クィンテロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia LLC
Original Assignee
Pharmacopeia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia LLC filed Critical Pharmacopeia LLC
Publication of JP2010510211A publication Critical patent/JP2010510211A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
JP2009537135A 2006-11-16 2006-11-16 免疫抑制用７−置換プリン誘導体 Withdrawn JP2010510211A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/061004 WO2008060301A1 (en) 2006-11-16 2006-11-16 7-substituted purine derivatives for immunosuppression

Publications (1)

Publication Number Publication Date
JP2010510211A true JP2010510211A (ja) 2010-04-02

Family

ID=38578618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537135A Withdrawn JP2010510211A (ja) 2006-11-16 2006-11-16 免疫抑制用７−置換プリン誘導体

Country Status (11)

Country Link
EP (1) EP2099800A1 (ko)
JP (1) JP2010510211A (ko)
KR (1) KR20100014271A (ko)
CN (1) CN101595110A (ko)
AU (1) AU2006350748A1 (ko)
BR (1) BRPI0622030A2 (ko)
CA (1) CA2669686A1 (ko)
CR (1) CR10870A (ko)
IL (1) IL198761A0 (ko)
MX (1) MX2009005194A (ko)
WO (1) WO2008060301A1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2754890C (en) 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
EP2419423A1 (en) 2009-04-14 2012-02-22 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
KR20120102601A (ko) 2009-10-20 2012-09-18 셀좀 리미티드 Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체
UA109775C2 (xx) 2009-10-29 2015-10-12 N-вмісні гетероарильні похідні як інгібітори jak3-кінази
SG184989A1 (en) 2010-04-30 2012-11-29 Cellzome Ltd Pyrazole compounds as jak inhibitors
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
RS55184B1 (sr) 2010-05-31 2017-01-31 Ono Pharmaceutical Co Derivat purinona kao inhibitor btk kinaze
US20130165426A1 (en) * 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
KR101227388B1 (ko) * 2010-09-09 2013-01-30 주식회사 만도 3웨이 형식의 저압 배기가스 재순환 밸브 구조
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
EP2736901A1 (en) 2011-07-28 2014-06-04 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013025628A1 (en) 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
HUE031094T2 (en) 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2015089218A1 (en) 2013-12-10 2015-06-18 David Wustrow Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
WO2015109285A1 (en) 2014-01-20 2015-07-23 Cleave Biosciences, Inc. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
EP3281943B1 (en) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Process for producing purinone derivative
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
KR20200009001A (ko) * 2017-05-17 2020-01-29 가부시끼가이샤 도꾸야마 디아미노벤젠 화합물의 제조 방법
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
KR102516260B1 (ko) * 2020-07-10 2023-03-31 울산과학기술원 Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
KR102579424B1 (ko) * 2021-02-19 2023-09-18 울산과학기술원 미토콘드리아 내부 축적이 증가된 trap1 선택적 억제제로서의 화합물 및 이의 용도
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704145B1 (en) * 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CN101142218B (zh) * 2005-02-03 2013-02-06 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并嘧啶
RU2007140903A (ru) * 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии

Also Published As

Publication number Publication date
MX2009005194A (es) 2009-11-10
BRPI0622030A2 (pt) 2014-04-22
AU2006350748A1 (en) 2008-05-22
EP2099800A1 (en) 2009-09-16
AU2006350748A2 (en) 2009-08-06
WO2008060301A1 (en) 2008-05-22
CN101595110A (zh) 2009-12-02
IL198761A0 (en) 2010-02-17
KR20100014271A (ko) 2010-02-10
CA2669686A1 (en) 2008-05-22
CR10870A (es) 2009-12-01

Similar Documents

Publication Publication Date Title
JP2010510211A (ja) 免疫抑制用７−置換プリン誘導体
US7884109B2 (en) Purine and imidazopyridine derivatives for immunosuppression
US20080119496A1 (en) 7-Substituted Purine Derivatives for Immunosuppression
US20070021443A1 (en) Purine and imidazopyridine derivatives for immunosuppression
US7915268B2 (en) 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
JP5816678B2 (ja) ＰＩ３Ｋδ阻害剤としての縮合誘導体
EP3523305B1 (en) Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
RU2652638C2 (ru) Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
US20100093748A1 (en) Substituted piperidines having protein kinase inhibiting activity
JP2012500805A (ja) 免疫抑制のための６−置換２−（ベンズイミダゾリル）プリンおよびプリノン誘導体ならびに６−置換２−（イミダゾロ［４，５−ｃ］ピリジニル）プリンおよびプリノン誘導体
EP2043655A2 (en) Purine and deazapurine derivatives as pharmaceutical compounds
WO2011075630A1 (en) Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2008039359A2 (en) Bicyclic pyrimidine kinase inhibitors
JP2017516855A (ja) 特定のタンパク質キナーゼ阻害剤
JP2009513678A (ja) 化合物
CA2922044A1 (en) Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
WO2009048474A1 (en) 2,7,9-substituted purinone derivatives for immunosuppression
CA3124815A1 (en) Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
US20200172536A1 (en) PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
EP4157844A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
WO2016127455A1 (zh) 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
CN114728963B (zh) 新型三唑吡啶衍生物和包括其的药物组合物

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120228